Alimta

... OSI / Genentech / Roche: Tarceva triumphs again - Pharmaceutical Business Review SEARCH THIS SITE IN All Of The Site News & Features Research Company Intelligence Go You are here: Home Article Home Sign up for free newsletters Features News Research Company Intelligence Research Store Browse By Industry Recent Research Best Sellers Industry Profiles Customer Service Company Intelligence Find A Company About This Site About This Site Advertise with us Contact us Add site to favorites Privacy policy For Your Site (XML) RSS Feed - Features RSS Feed - Companies OSI / Genentech / Roche: Tarceva triumphs again A study has revealed that Tarceva benefits elderly lung cancer patients.

19 Sep 2005, 17:16 GMT - The results of a phase II study have suggested that OSI Pharmaceuticals, Genentech and Roche's Tarceva may be particularly beneficial in elderly patients with previously untreated lung cancer.

These results may increase off-label first-line use of the drug in such patients, although Tarceva's high price may hinder uptake in this setting.

The results of the phase II trial demonstrated that Tarceva (erlotinib) has activity as a first-line therapy in elderly (over 70 years) non-small cell lung cancer (NSCLC) patients.

In the study, a total of 80 patients were treated with single-agent Tarceva between 2003 and 2005, and 69 patients were evaluated for best response.

Although no patients demonstrated a compl...

Read more...